ArticleEJNMMI physics2020
Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management.
Article in EJNMMI physics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Safety and dosimetry of [European journal of nuclear medicine and molecular imaging · 2025Trial
- Dosimetry and pharmacokinetics of [European journal of nuclear medicine and molecular imaging · 2024Trial
- Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-basedEuropean journal of nuclear medicine and molecular imaging · 2022Trial
- Impact of simulation settings, time-activity curve integration range, and imaging time points on full Monte Carlo-basedAnnals of nuclear medicine · 2026Article
- Validation of Simplified Renal Dosimetry Protocols forMolecular imaging and radionuclide therapy · 2026Article
- Inter-institutional variability in kidney dosimetry duringRadiological physics and technology · 2026Article
- On the reduction of imaging time-points for dosimetry in radionuclide therapy.EJNMMI physics · 2025Article
- A Monte Carlo study comparing dead-time losses of a gamma camera between tungsten functional paper and lead sheet for dosimetry in targeted radionuclide therapy with Lu-177.Annals of nuclear medicine · 2025Article
- A proof-of-concept study of personalized dosimetry for targeted radioligand therapy using pre-treatment diagnostic dynamic PET/CT and Monte Carlo simulation.Frontiers in oncology · 2025Article
- Heterogeneity of absorbed dose distribution in kidney tissues and dose-response modelling of nephrotoxicity in radiopharmaceutical therapy with beta-particle emitters: A review.Zeitschrift fur medizinische Physik · 2024Review
- A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?EJNMMI physics · 2024Review
- SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients.European journal of nuclear medicine and molecular imaging · 2023Article
- A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [European journal of nuclear medicine and molecular imaging · 2023Article
- The effect of long-acting somatostatin analogues on the uptake of [European journal of nuclear medicine and molecular imaging · 2023Article
- Towards accurateEJNMMI physics · 2023Article
- Dosimetry in Radiopharmaceutical Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Review
- Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle forEJNMMI physics · 2022Article
- EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands.European journal of nuclear medicine and molecular imaging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAfter each cycle of [
resultsThe best agreement for the cumulative doses absorbed by the kidneys, bone marrow, liver, spleen, and tumors with the conventional protocol was obtained with the (t
conclusionThese preliminary results demonstrate that dosimetry calculations using two quantitative SPECT/CT studies acquired at 24 and 168 h after the first PRRT cycle are feasible and are in good agreement with the standard imaging protocol with no change in patient management decisions, while enabling improved patient comfort and reduced scanner and staff time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.